Lin C, Hsu J, Hsu Y, Fan K, Wu S, Lin M
J Enzyme Inhib Med Chem. 2025; 40(1):2468355.
PMID: 40013582
PMC: 11869342.
DOI: 10.1080/14756366.2025.2468355.
Feller F, Honin I, Miranda M, Weber H, Henze S, Hanl M
J Med Chem. 2025; 68(2):1824-1843.
PMID: 39804678
PMC: 11780399.
DOI: 10.1021/acs.jmedchem.4c02569.
Cao D, Zhou X, Guo Q, Xiang M, Bao M, He B
Biomark Res. 2024; 12(1):142.
PMID: 39563472
PMC: 11575089.
DOI: 10.1186/s40364-024-00687-6.
Zhong G, Chang X, Xie W, Zhou X
Signal Transduct Target Ther. 2024; 9(1):308.
PMID: 39500878
PMC: 11539257.
DOI: 10.1038/s41392-024-02004-x.
Zhang C, He Y, Sun X, Wei W, Liu Y, Rao Y
Acta Mater Med. 2024; 2(4):409-429.
PMID: 39221114
PMC: 11364368.
DOI: 10.15212/amm-2023-0039.
PROTAC Beyond Cancer- Exploring the New Therapeutic Potential of Proteolysis Targeting Chimeras.
Bhole R, Patil S, Kapare H, Chikhale R, Gurav S
Curr Top Med Chem. 2024; 24(23):2050-2073.
PMID: 38963108
DOI: 10.2174/0115680266309968240621072550.
The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods.
Curcio A, Rocca R, Alcaro S, Artese A
Pharmaceuticals (Basel). 2024; 17(5).
PMID: 38794190
PMC: 11124352.
DOI: 10.3390/ph17050620.
Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells.
Brennan P, Saunders R, Spanou M, Serafini M, Sun L, Heger G
bioRxiv. 2024; .
PMID: 38559242
PMC: 10979945.
DOI: 10.1101/2024.03.15.585309.
Degraders in epigenetic therapy: PROTACs and beyond.
Dai X, Ji S, Fu M, Liu G, Liu H, Wang S
Theranostics. 2024; 14(4):1464-1499.
PMID: 38389844
PMC: 10879860.
DOI: 10.7150/thno.92526.
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.
Peng X, Hu Z, Zeng L, Zhang M, Xu C, Lu B
Acta Pharm Sin B. 2024; 14(2):533-578.
PMID: 38322348
PMC: 10840439.
DOI: 10.1016/j.apsb.2023.09.003.
Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer.
Vuletic A, Mirjacic Martinovic K, Spasic J
Pharmaceutics. 2024; 16(1).
PMID: 38258065
PMC: 10818982.
DOI: 10.3390/pharmaceutics16010054.
Targeted Protein Degradation of Histone Deacetylases by Hydrophobically Tagged Inhibitors.
Feller F, Hansen F
ACS Med Chem Lett. 2023; 14(12):1863-1868.
PMID: 38116436
PMC: 10726458.
DOI: 10.1021/acsmedchemlett.3c00468.
Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues.
Pichlak M, Sobierajski T, Blazewska K, Gendaszewska-Darmach E
J Enzyme Inhib Med Chem. 2023; 38(1):2254012.
PMID: 37667522
PMC: 10481767.
DOI: 10.1080/14756366.2023.2254012.
PROTAC chemical probes for histone deacetylase enzymes.
Patel U, Smalley J, Hodgkinson J
RSC Chem Biol. 2023; 4(9):623-634.
PMID: 37654508
PMC: 10467623.
DOI: 10.1039/d3cb00105a.
HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation.
Xiao Y, Hale S, Awasthee N, Meng C, Zhang X, Liu Y
Cell Chem Biol. 2023; 30(11):1421-1435.e12.
PMID: 37572669
PMC: 10802846.
DOI: 10.1016/j.chembiol.2023.07.010.
Targeting histone deacetylases for cancer therapy: Trends and challenges.
Liang T, Wang F, Elhassan R, Cheng Y, Tang X, Chen W
Acta Pharm Sin B. 2023; 13(6):2425-2463.
PMID: 37425042
PMC: 10326266.
DOI: 10.1016/j.apsb.2023.02.007.
Chemically induced degradation of epigenetic targets.
Kabir M, Yu X, Umit Kaniskan H, Jin J
Chem Soc Rev. 2023; 52(13):4313-4342.
PMID: 37314393
PMC: 10330942.
DOI: 10.1039/d3cs00100h.
Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?.
Cieslak M, Slowianek M
Pharmaceutics. 2023; 15(3).
PMID: 36986673
PMC: 10053963.
DOI: 10.3390/pharmaceutics15030812.
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A, Zhou H, Yang J, Li M, Niu T
Signal Transduct Target Ther. 2023; 8(1):71.
PMID: 36797244
PMC: 9935927.
DOI: 10.1038/s41392-023-01342-6.
Development of Human Carbonic Anhydrase II Heterobifunctional Degraders.
OHerin C, Moriuchi Y, Bemis T, Kohlbrand A, Burkart M, Cohen S
J Med Chem. 2023; 66(4):2789-2803.
PMID: 36735827
PMC: 9969396.
DOI: 10.1021/acs.jmedchem.2c01843.